400 results on '"John M. Buatti"'
Search Results
2. ASTRO Supports Access to Evidence-Based Cancer Care for All Patients, Regardless of Pregnancy Status, and Protection for Physicians Recommending and Providing Evidence-Based Care
- Author
-
Geraldine M. Jacobson, Gopal K. Bajaj, John M. Buatti, Laura Dawson, Curtiland Deville, Thomas J. Eichler, Beth Erickson, Eric Ford, Iris C. Gibbs, Constantine Mantz, Brian Marples, Jeff M. Michalski, Howard Sandler, Benjamin Smith, Neha Vapiwala, and Catheryn Yashar
- Subjects
Cancer Research ,Evidence-Based Medicine ,Radiation ,Oncology ,Pregnancy ,Neoplasms ,Physicians ,Humans ,Female ,Radiology, Nuclear Medicine and imaging - Published
- 2022
- Full Text
- View/download PDF
3. Quantification of uptake in pelvis F‐18 FLT PET‐CT images using a 3D localization and segmentation CNN
- Author
-
Xiaofan Xiong, Brian J. Smith, Stephen A. Graves, John J. Sunderland, Michael M. Graham, Brandie A. Gross, John M. Buatti, and Reinhard R. Beichel
- Subjects
Positron Emission Tomography Computed Tomography ,Image Processing, Computer-Assisted ,Neural Networks, Computer ,General Medicine ,Radiopharmaceuticals ,Article ,Dideoxynucleosides ,Pelvis - Abstract
PURPOSE: The purpose of this work was to develop and validate a deep convolutional neural network (CNN) approach for the automated pelvis segmentation in computed tomography (CT) scans to enable the quantification of active pelvic bone marrow by means of Fluorothymidine F-18 (FLT) tracer uptake measurement in positron emission tomography (PET) scans. This quantification is a critical step in calculating bone marrow dose for radiopharmaceutical therapy clinical applications as well as external beam radiation doses. METHODS: An approach for the combined localization and segmentation of the pelvis in CT volumes of varying sizes, ranging from full-body to pelvis CT scans, was developed that utilizes a novel CNN architecture in combination with a random sampling strategy. The method was validated on 34 planning CT scans and 106 full-body FLT PET-CT scans using a cross-validation strategy. Specifically, two different training and CNN application options were studied, quantitatively assessed, and statistically compared. RESULTS: The proposed method was able to successfully locate and segment the pelvis in all test cases. On all data sets, an average Dice coefficient of 0.9396±0.0182 or better was achieved. The relative tracer uptake measurement error ranged between 0.065 and 0.204%. The proposed approach is time efficient and shows a reduction in runtime of up to 95% compared to a standard U-Net-based approach without a localization component. CONCLUSIONS: The proposed method enables the efficient calculation of FLT uptake in the pelvis. Thus, it represents a valuable tool to facilitate bone marrow preserving adaptive radiation therapy and radiopharmaceutical dose calculation. Furthermore, the method can be adapted to process other bone structures as well as organs.
- Published
- 2022
- Full Text
- View/download PDF
4. Supplementary Tables from First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
- Author
-
John M. Buatti, Douglas R. Spitz, Brian J. Smith, Mindi J. TenNapel, Garry R. Buettner, Brett A. Wagner, Daniel Berg, Joseph J. Cullen, Karra A. Jones, Joseph M. Caster, Steven N. Seyedin, Kranti A. Mapuskar, Matthew A. Howard, Jeremy D. Greenlee, Sandy Vollstedt, Nancy Hollenbeck, Heather Brown, Thomas Carlisle, Raymond Hohl, Sonia Sandhu, Varun Monga, Mark C. Smith, Kellie L. Bodeker, and Bryan G. Allen
- Abstract
Supplementary Table 1. Description of radiation treatment volumes (GTV, CTV, and PTV) Supplementary Table 2. Description of dose to organs at risk and treatment interruptions Supplemental Table 3. Subject count for key steps within the RT-phase of the clinical trial Supplemental Table 4. Subject count for key steps within the ADJ-phase of the clinical trial
- Published
- 2023
- Full Text
- View/download PDF
5. Supplementary Figure 1 from Ketogenic Diets Enhance Oxidative Stress and Radio-Chemo-Therapy Responses in Lung Cancer Xenografts
- Author
-
Melissa A. Fath, Douglas R. Spitz, Brian J. Smith, Luke I. Szweda, Anna M. Button, Kaleigh E. Lindholm, Kristin E. Brandt, John M. Buatti, Sudershan K. Bhatia, and Bryan G. Allen
- Abstract
Supplementary Figure 1 - PDF file 911K, Mouse weights
- Published
- 2023
- Full Text
- View/download PDF
6. Supplementary Figure Legend from Ketogenic Diets Enhance Oxidative Stress and Radio-Chemo-Therapy Responses in Lung Cancer Xenografts
- Author
-
Melissa A. Fath, Douglas R. Spitz, Brian J. Smith, Luke I. Szweda, Anna M. Button, Kaleigh E. Lindholm, Kristin E. Brandt, John M. Buatti, Sudershan K. Bhatia, and Bryan G. Allen
- Abstract
Supplementary Figure Legend - PDF file 71K, Supplementary Figure Legend
- Published
- 2023
- Full Text
- View/download PDF
7. Table S1 from Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer
- Author
-
Joseph J. Cullen, Bryan G. Allen, Heather A. Brown, Sandy Vollstedt, Kellie L. Bodeker, Daniel J. Berg, John M. Buatti, Douglas R. Spitz, Brianne R. O’Leary, Katherine Gibson-Corley, Juan Du, Brett A. Wagner, Garry R. Buettner, Samuel R. Schroeder, Justin G. Wilkes, and Matthew S. Alexander
- Abstract
Radiation induced intestinal damage histology and collagen deposition information.
- Published
- 2023
- Full Text
- View/download PDF
8. Supplementary Legend from First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
- Author
-
John M. Buatti, Douglas R. Spitz, Brian J. Smith, Mindi J. TenNapel, Garry R. Buettner, Brett A. Wagner, Daniel Berg, Joseph J. Cullen, Karra A. Jones, Joseph M. Caster, Steven N. Seyedin, Kranti A. Mapuskar, Matthew A. Howard, Jeremy D. Greenlee, Sandy Vollstedt, Nancy Hollenbeck, Heather Brown, Thomas Carlisle, Raymond Hohl, Sonia Sandhu, Varun Monga, Mark C. Smith, Kellie L. Bodeker, and Bryan G. Allen
- Abstract
Supplementary Legend
- Published
- 2023
- Full Text
- View/download PDF
9. Figure S1 from Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer
- Author
-
Joseph J. Cullen, Bryan G. Allen, Heather A. Brown, Sandy Vollstedt, Kellie L. Bodeker, Daniel J. Berg, John M. Buatti, Douglas R. Spitz, Brianne R. O’Leary, Katherine Gibson-Corley, Juan Du, Brett A. Wagner, Garry R. Buettner, Samuel R. Schroeder, Justin G. Wilkes, and Matthew S. Alexander
- Abstract
The effect of ascorbate and catalase on clonogenic cell survival in PDAC.
- Published
- 2023
- Full Text
- View/download PDF
10. Figure S2 from Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer
- Author
-
Joseph J. Cullen, Bryan G. Allen, Heather A. Brown, Sandy Vollstedt, Kellie L. Bodeker, Daniel J. Berg, John M. Buatti, Douglas R. Spitz, Brianne R. O’Leary, Katherine Gibson-Corley, Juan Du, Brett A. Wagner, Garry R. Buettner, Samuel R. Schroeder, Justin G. Wilkes, and Matthew S. Alexander
- Abstract
Plasma ascorbate concentrations.
- Published
- 2023
- Full Text
- View/download PDF
11. Data from Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy
- Author
-
Bryan G. Allen, Douglas R. Spitz, Prabhat C. Goswami, John M. Buatti, Frederick E. Domann, Varun Monga, Muhammad Furqan, Taher Abu Hejleh, Stefan Strack, Dennis P. Riley, Joshua D. Schoenfeld, Kyle H. Flippo, and Kranti A. Mapuskar
- Abstract
Elderly cancer patients treated with ionizing radiation (IR) or chemotherapy experience more frequent and greater normal tissue toxicity relative to younger patients. The current study demonstrates that exponentially growing fibroblasts from elderly (old) male donor subjects (70, 72, and 78 years) are significantly more sensitive to clonogenic killing mediated by platinum-based chemotherapy and IR (∼70%–80% killing) relative to young fibroblasts (5 months and 1 year; ∼10%–20% killing) and adult fibroblasts (20 years old; ∼10%–30% killing). Old fibroblasts also displayed significantly increased (2–4-fold) steady-state levels of O2•−, O2 consumption, and mitochondrial membrane potential as well as significantly decreased (40%–50%) electron transport chain (ETC) complex I, II, IV, V, and aconitase (70%) activities, decreased ATP levels, and significantly altered mitochondrial structure. Following adenoviral-mediated overexpression of SOD2 activity (5–7-fold), mitochondrial ETC activity and aconitase activity were restored, demonstrating a role for mitochondrial O2•− in these effects. Old fibroblasts also demonstrated elevated levels of endogenous DNA damage that were increased following treatment with IR and chemotherapy. Most importantly, treatment with the small-molecule, superoxide dismutase mimetic (GC4419; 0.25 μmol/L) significantly mitigated the increased sensitivity of old fibroblasts to IR and chemotherapy and partially restored mitochondrial function without affecting IR or chemotherapy-induced cancer cell killing. These results support the hypothesis that age-associated increased O2•− and resulting DNA damage mediate the increased susceptibility of old fibroblasts to IR and chemotherapy that can be mitigated by GC4419. Cancer Res; 77(18); 5054–67. ©2017 AACR.
- Published
- 2023
- Full Text
- View/download PDF
12. Figure S3 from Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer
- Author
-
Joseph J. Cullen, Bryan G. Allen, Heather A. Brown, Sandy Vollstedt, Kellie L. Bodeker, Daniel J. Berg, John M. Buatti, Douglas R. Spitz, Brianne R. O’Leary, Katherine Gibson-Corley, Juan Du, Brett A. Wagner, Garry R. Buettner, Samuel R. Schroeder, Justin G. Wilkes, and Matthew S. Alexander
- Abstract
Hemoglobin concentrations.
- Published
- 2023
- Full Text
- View/download PDF
13. Supplementary Figure 1 from Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy
- Author
-
Bryan G. Allen, Douglas R. Spitz, Prabhat C. Goswami, John M. Buatti, Frederick E. Domann, Varun Monga, Muhammad Furqan, Taher Abu Hejleh, Stefan Strack, Dennis P. Riley, Joshua D. Schoenfeld, Kyle H. Flippo, and Kranti A. Mapuskar
- Abstract
Molecular structure of SOD mimetic, characterization of young and old dermal fibroblasts, and sensitivity of young and old dermal fibroblasts to cancer therapies.
- Published
- 2023
- Full Text
- View/download PDF
14. Supplementary Figure 1 from First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
- Author
-
John M. Buatti, Douglas R. Spitz, Brian J. Smith, Mindi J. TenNapel, Garry R. Buettner, Brett A. Wagner, Daniel Berg, Joseph J. Cullen, Karra A. Jones, Joseph M. Caster, Steven N. Seyedin, Kranti A. Mapuskar, Matthew A. Howard, Jeremy D. Greenlee, Sandy Vollstedt, Nancy Hollenbeck, Heather Brown, Thomas Carlisle, Raymond Hohl, Sonia Sandhu, Varun Monga, Mark C. Smith, Kellie L. Bodeker, and Bryan G. Allen
- Abstract
Supplemental Figure 1: P-AscH- treatment in combination with RT and TMZ decreases the systemic the systemic oxidaitive stress marker 4-hydroxy-2-nonenal modified proteins. S1A-SAB.
- Published
- 2023
- Full Text
- View/download PDF
15. Table S2 from Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer
- Author
-
Joseph J. Cullen, Bryan G. Allen, Heather A. Brown, Sandy Vollstedt, Kellie L. Bodeker, Daniel J. Berg, John M. Buatti, Douglas R. Spitz, Brianne R. O’Leary, Katherine Gibson-Corley, Juan Du, Brett A. Wagner, Garry R. Buettner, Samuel R. Schroeder, Justin G. Wilkes, and Matthew S. Alexander
- Abstract
Additional Clinical Data for Comparator Patients.
- Published
- 2023
- Full Text
- View/download PDF
16. Data from Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer
- Author
-
Joseph J. Cullen, Bryan G. Allen, Heather A. Brown, Sandy Vollstedt, Kellie L. Bodeker, Daniel J. Berg, John M. Buatti, Douglas R. Spitz, Brianne R. O’Leary, Katherine Gibson-Corley, Juan Du, Brett A. Wagner, Garry R. Buettner, Samuel R. Schroeder, Justin G. Wilkes, and Matthew S. Alexander
- Abstract
Chemoradiation therapy is the mainstay for treatment of locally advanced, borderline resectable pancreatic cancer. Pharmacologic ascorbate (P-AscH−, i.e., intravenous infusions of ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations capable of selective cytotoxicity to tumor cells. In doses achievable in humans, P-AscH− decreases the viability and proliferative capacity of pancreatic cancer via a hydrogen peroxide (H2O2)-mediated mechanism. In this study, we demonstrate that P-AscH− radiosensitizes pancreatic cancer cells but inhibits radiation-induced damage to normal cells. Specifically, radiation-induced decreases in clonogenic survival and double-stranded DNA breaks in tumor cells, but not in normal cells, were enhanced by P-AscH−, while radiation-induced intestinal damage, collagen deposition, and oxidative stress were also reduced with P-AscH− in normal tissue. We also report on our first-in-human phase I trial that infused P-AscH− during the radiotherapy “beam on.” Specifically, treatment with P-AscH− increased median overall survival compared with our institutional average (21.7 vs. 12.7 months, P = 0.08) and the E4201 trial (21.7 vs. 11.1 months). Progression-free survival in P-AscH−–treated subjects was also greater than our institutional average (13.7 vs. 4.6 months, P < 0.05) and the E4201 trial (6.0 months). Results indicated that P-AscH− in combination with gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma is safe and well tolerated with suggestions of efficacy. Because of the potential effect size and minimal toxicity, our findings suggest that investigation of P-AscH− efficacy is warranted in a phase II clinical trial.Significance:These findings demonstrate that pharmacologic ascorbate enhances pancreatic tumor cell radiation cytotoxicity in addition to offering potential protection from radiation damage in normal surrounding tissue, making it an optimal agent for improving treatment of locally advanced pancreatic adenocarcinoma.
- Published
- 2023
- Full Text
- View/download PDF
17. Data from First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
- Author
-
John M. Buatti, Douglas R. Spitz, Brian J. Smith, Mindi J. TenNapel, Garry R. Buettner, Brett A. Wagner, Daniel Berg, Joseph J. Cullen, Karra A. Jones, Joseph M. Caster, Steven N. Seyedin, Kranti A. Mapuskar, Matthew A. Howard, Jeremy D. Greenlee, Sandy Vollstedt, Nancy Hollenbeck, Heather Brown, Thomas Carlisle, Raymond Hohl, Sonia Sandhu, Varun Monga, Mark C. Smith, Kellie L. Bodeker, and Bryan G. Allen
- Abstract
Purpose:Standard treatment for glioblastoma (GBM) includes surgery, radiation therapy (RT), and temozolomide (TMZ), yielding a median overall survival (OS) of approximately 14 months. Preclinical models suggest that pharmacologic ascorbate (P-AscH−) enhances RT/TMZ antitumor effect in GBM. We evaluated the safety of adding P-AscH− to standard RT/TMZ therapy.Patients and Methods:This first-in-human trial was divided into an RT phase (concurrent RT/TMZ/P-AscH−) and an adjuvant (ADJ) phase (post RT/TMZ/P-AscH− phase). Eight P-AscH− dose cohorts were evaluated in the RT phase until targeted plasma ascorbate levels were achieved (≥20 mmol/L). In the ADJ phase, P-AscH− doses were escalated in each subject at each cycle until plasma concentrations were ≥20 mmol/L. P-AscH− was infused 3 times weekly during the RT phase and 2 times weekly during the ADJ phase continuing for six cycles or until disease progression. Adverse events were quantified by CTCAE (v4.03).Results:Eleven subjects were evaluable. No dose-limiting toxicities occurred. Observed toxicities were consistent with historical controls. Adverse events related to study drug were dry mouth and chills. Targeted ascorbate plasma levels of 20 mmol/L were achieved in the 87.5 g cohort; diminishing returns were realized in higher dose cohorts. Median progression-free survival (PFS) was 9.4 months and median OS was 18 months. In subjects with undetectable MGMT promoter methylation (n = 8), median PFS was 10 months and median OS was 23 months.Conclusions:P-AscH−/RT/TMZ is safe with promising clinical outcomes warranting further investigation.
- Published
- 2023
- Full Text
- View/download PDF
18. Data from Ketogenic Diets Enhance Oxidative Stress and Radio-Chemo-Therapy Responses in Lung Cancer Xenografts
- Author
-
Melissa A. Fath, Douglas R. Spitz, Brian J. Smith, Luke I. Szweda, Anna M. Button, Kaleigh E. Lindholm, Kristin E. Brandt, John M. Buatti, Sudershan K. Bhatia, and Bryan G. Allen
- Abstract
Purpose: Ketogenic diets are high in fat and low in carbohydrates as well as protein which forces cells to rely on lipid oxidation and mitochondrial respiration rather than glycolysis for energy metabolism. Cancer cells (relative to normal cells) are believed to exist in a state of chronic oxidative stress mediated by mitochondrial metabolism. The current study tests the hypothesis that ketogenic diets enhance radio-chemo-therapy responses in lung cancer xenografts by enhancing oxidative stress.Experimental Design: Mice bearing NCI-H292 and A549 lung cancer xenografts were fed a ketogenic diet (KetoCal 4:1 fats: proteins+carbohydrates) and treated with either conventionally fractionated (1.8–2 Gy) or hypofractionated (6 Gy) radiation as well as conventionally fractionated radiation combined with carboplatin. Mice weights and tumor size were monitored. Tumors were assessed for immunoreactive 4-hydroxy-2-nonenal-(4HNE)–modified proteins as a marker of oxidative stress as well as proliferating cell nuclear antigen (PCNA) and γH2AX as indices of proliferation and DNA damage, respectively.Results: The ketogenic diets combined with radiation resulted in slower tumor growth in both NCI-H292 and A549 xenografts (P < 0.05), relative to radiation alone. The ketogenic diet also slowed tumor growth when combined with carboplatin and radiation, relative to control. Tumors from animals fed a ketogenic diet in combination with radiation showed increases in oxidative damage mediated by lipid peroxidation as determined by 4HNE-modified proteins as well as decreased proliferation as assessed by decreased immunoreactive PCNA.Conclusions: These results show that a ketogenic diet enhances radio-chemo-therapy responses in lung cancer xenografts by a mechanism that may involve increased oxidative stress. Clin Cancer Res; 19(14); 3905–13. ©2013 AACR.
- Published
- 2023
- Full Text
- View/download PDF
19. Author Correction: Federated learning enables big data for rare cancer boundary detection
- Author
-
Sarthak Pati, Ujjwal Baid, Brandon Edwards, Micah Sheller, Shih-Han Wang, G. Anthony Reina, Patrick Foley, Alexey Gruzdev, Deepthi Karkada, Christos Davatzikos, Chiharu Sako, Satyam Ghodasara, Michel Bilello, Suyash Mohan, Philipp Vollmuth, Gianluca Brugnara, Chandrakanth J. Preetha, Felix Sahm, Klaus Maier-Hein, Maximilian Zenk, Martin Bendszus, Wolfgang Wick, Evan Calabrese, Jeffrey Rudie, Javier Villanueva-Meyer, Soonmee Cha, Madhura Ingalhalikar, Manali Jadhav, Umang Pandey, Jitender Saini, John Garrett, Matthew Larson, Robert Jeraj, Stuart Currie, Russell Frood, Kavi Fatania, Raymond Y. Huang, Ken Chang, Carmen Balaña, Jaume Capellades, Josep Puig, Johannes Trenkler, Josef Pichler, Georg Necker, Andreas Haunschmidt, Stephan Meckel, Gaurav Shukla, Spencer Liem, Gregory S. Alexander, Joseph Lombardo, Joshua D. Palmer, Adam E. Flanders, Adam P. Dicker, Haris I. Sair, Craig K. Jones, Archana Venkataraman, Meirui Jiang, Tiffany Y. So, Cheng Chen, Pheng Ann Heng, Qi Dou, Michal Kozubek, Filip Lux, Jan Michálek, Petr Matula, Miloš Keřkovský, Tereza Kopřivová, Marek Dostál, Václav Vybíhal, Michael A. Vogelbaum, J. Ross Mitchell, Joaquim Farinhas, Joseph A. Maldjian, Chandan Ganesh Bangalore Yogananda, Marco C. Pinho, Divya Reddy, James Holcomb, Benjamin C. Wagner, Benjamin M. Ellingson, Timothy F. Cloughesy, Catalina Raymond, Talia Oughourlian, Akifumi Hagiwara, Chencai Wang, Minh-Son To, Sargam Bhardwaj, Chee Chong, Marc Agzarian, Alexandre Xavier Falcão, Samuel B. Martins, Bernardo C. A. Teixeira, Flávia Sprenger, David Menotti, Diego R. Lucio, Pamela LaMontagne, Daniel Marcus, Benedikt Wiestler, Florian Kofler, Ivan Ezhov, Marie Metz, Rajan Jain, Matthew Lee, Yvonne W. Lui, Richard McKinley, Johannes Slotboom, Piotr Radojewski, Raphael Meier, Roland Wiest, Derrick Murcia, Eric Fu, Rourke Haas, John Thompson, David Ryan Ormond, Chaitra Badve, Andrew E. Sloan, Vachan Vadmal, Kristin Waite, Rivka R. Colen, Linmin Pei, Murat Ak, Ashok Srinivasan, J. Rajiv Bapuraj, Arvind Rao, Nicholas Wang, Ota Yoshiaki, Toshio Moritani, Sevcan Turk, Joonsang Lee, Snehal Prabhudesai, Fanny Morón, Jacob Mandel, Konstantinos Kamnitsas, Ben Glocker, Luke V. M. Dixon, Matthew Williams, Peter Zampakis, Vasileios Panagiotopoulos, Panagiotis Tsiganos, Sotiris Alexiou, Ilias Haliassos, Evangelia I. Zacharaki, Konstantinos Moustakas, Christina Kalogeropoulou, Dimitrios M. Kardamakis, Yoon Seong Choi, Seung-Koo Lee, Jong Hee Chang, Sung Soo Ahn, Bing Luo, Laila Poisson, Ning Wen, Pallavi Tiwari, Ruchika Verma, Rohan Bareja, Ipsa Yadav, Jonathan Chen, Neeraj Kumar, Marion Smits, Sebastian R. van der Voort, Ahmed Alafandi, Fatih Incekara, Maarten M. J. Wijnenga, Georgios Kapsas, Renske Gahrmann, Joost W. Schouten, Hendrikus J. Dubbink, Arnaud J. P. E. Vincent, Martin J. van den Bent, Pim J. French, Stefan Klein, Yading Yuan, Sonam Sharma, Tzu-Chi Tseng, Saba Adabi, Simone P. Niclou, Olivier Keunen, Ann-Christin Hau, Martin Vallières, David Fortin, Martin Lepage, Bennett Landman, Karthik Ramadass, Kaiwen Xu, Silky Chotai, Lola B. Chambless, Akshitkumar Mistry, Reid C. Thompson, Yuriy Gusev, Krithika Bhuvaneshwar, Anousheh Sayah, Camelia Bencheqroun, Anas Belouali, Subha Madhavan, Thomas C. Booth, Alysha Chelliah, Marc Modat, Haris Shuaib, Carmen Dragos, Aly Abayazeed, Kenneth Kolodziej, Michael Hill, Ahmed Abbassy, Shady Gamal, Mahmoud Mekhaimar, Mohamed Qayati, Mauricio Reyes, Ji Eun Park, Jihye Yun, Ho Sung Kim, Abhishek Mahajan, Mark Muzi, Sean Benson, Regina G. H. Beets-Tan, Jonas Teuwen, Alejandro Herrera-Trujillo, Maria Trujillo, William Escobar, Ana Abello, Jose Bernal, Jhon Gómez, Joseph Choi, Stephen Baek, Yusung Kim, Heba Ismael, Bryan Allen, John M. Buatti, Aikaterini Kotrotsou, Hongwei Li, Tobias Weiss, Michael Weller, Andrea Bink, Bertrand Pouymayou, Hassan F. Shaykh, Joel Saltz, Prateek Prasanna, Sampurna Shrestha, Kartik M. Mani, David Payne, Tahsin Kurc, Enrique Pelaez, Heydy Franco-Maldonado, Francis Loayza, Sebastian Quevedo, Pamela Guevara, Esteban Torche, Cristobal Mendoza, Franco Vera, Elvis Ríos, Eduardo López, Sergio A. Velastin, Godwin Ogbole, Mayowa Soneye, Dotun Oyekunle, Olubunmi Odafe-Oyibotha, Babatunde Osobu, Mustapha Shu’aibu, Adeleye Dorcas, Farouk Dako, Amber L. Simpson, Mohammad Hamghalam, Jacob J. Peoples, Ricky Hu, Anh Tran, Danielle Cutler, Fabio Y. Moraes, Michael A. Boss, James Gimpel, Deepak Kattil Veettil, Kendall Schmidt, Brian Bialecki, Sailaja Marella, Cynthia Price, Lisa Cimino, Charles Apgar, Prashant Shah, Bjoern Menze, Jill S. Barnholtz-Sloan, Jason Martin, and Spyridon Bakas
- Subjects
Multidisciplinary ,General Physics and Astronomy ,610 Medicine & health ,General Chemistry ,610 Medizin und Gesundheit ,General Biochemistry, Genetics and Molecular Biology - Published
- 2023
- Full Text
- View/download PDF
20. Initial clinical applications treating pediatric and adolescent patients using MR-guided radiotherapy
- Author
-
Margaret M. Kozak, David Crompton, Brandie A. Gross, Lyndsay Harshman, David Dickens, Jeffrey Snyder, Andrew Shepard, Joël St-Aubin, David Dunkerley, Daniel Hyer, and John M. Buatti
- Subjects
Cancer Research ,Oncology - Abstract
PurposeTo demonstrate the clinical applications and feasibility of online adaptive magnetic resonance image guided radiotherapy (MRgRT) in the pediatric, adolescent and young adult (AYA) population.MethodsThis is a retrospective case series of patients enrolled onto a prospective study. All pediatric (age < 18) and AYA patients (age< 30), treated on the Elekta Unity MR linear accelerator (MRL) from 2019 to 2021 were enrolled onto a prospective registry. Rationale for MRgRT included improved visualization of and alignment to the primary tumor, re-irradiation in a critical area, ability to use smaller margins, and need for daily adaptive replanning to minimize dose to adjacent critical structures. Step-and-shoot intensity-modulated radiation treatment (IMRT) plans were generated for all Unity patients with a dose grid of 3 mm and a statistical uncertainty of < 1% per plan.ResultsA total of 15 pediatric and AYA patients have been treated with median age of 13 years (range: 6 mos - 27 yrs). Seven patients were ConclusionMRgRT was well-tolerated by pediatric and AYA patients. There was no increased use of anesthesia outside of our usual practice. Dosimetric advantages were seen for patients with tumors in critical locations such as adjacent to or involving optic structures, stomach, kidney, bowel, and heart.
- Published
- 2022
- Full Text
- View/download PDF
21. Representative random sampling: an empirical evaluation of a novel bin stratification method for model performance estimation
- Author
-
Michael C. Rendleman, Brian J. Smith, Guadalupe Canahuate, Terry A. Braun, John M. Buatti, and Thomas L. Casavant
- Subjects
Statistics and Probability ,Computational Theory and Mathematics ,Statistics, Probability and Uncertainty ,Theoretical Computer Science - Abstract
High-dimensional cancer data can be burdensome to analyze, with complex relationships between molecular measurements, clinical diagnostics, and treatment outcomes. Data-driven computational approaches may be key to identifying relationships with potential clinical or research use. To this end, reliable comparison of feature engineering approaches in their ability to support machine learning survival modeling is crucial. With the limited number of cases often present in multi-omics datasets (“big p, little n,” or many features, few subjects), a resampling approach such as cross validation (CV) would provide robust model performance estimates at the cost of flexibility in intermediate assessments and exploration in feature engineering approaches. A holdout (HO) estimation approach, however, would permit this flexibility at the expense of reliability. To provide more reliable HO-based model performance estimates, we propose a novel sampling procedure: representative random sampling (RRS). RRS is a special case of continuous bin stratification which minimizes significant relationships between random HO groupings (or CV folds) and a continuous outcome. Monte Carlo simulations used to evaluate RRS on synthetic molecular data indicated that RRS-based HO (RRHO) yields statistically significant reductions in error and bias when compared with standard HO. Similarly, more consistent reductions are observed with RRS-based CV. While resampling approaches are the ideal choice for performance estimation with limited data, RRHO can enable more reliable exploratory feature engineering than standard HO.
- Published
- 2022
- Full Text
- View/download PDF
22. Reduced blood flow by laser speckle flowgraphy after 125I-plaque brachytherapy for uveal melanoma
- Author
-
Michelle R. Tamplin, Jui-Kai Wang, Anthony H. Vitale, Ryuya Hashimoto, Mona K. Garvin, Elaine M. Binkley, Daniel E. Hyer, John M. Buatti, H. Culver Boldt, Randy H. Kardon, and Isabella M. Grumbach
- Subjects
Ophthalmology ,General Medicine - Abstract
Background To determine whether reductions in retinal and choroidal blood flow measured by laser speckle flowgraphy are detected after 125I-plaque brachytherapy for uveal melanoma. Methods In a cross-sectional study, retinal and choroidal blood flow were measured using laser speckle flowgraphy in 25 patients after treatment with 125I-plaque brachytherapy for uveal melanoma. Flow was analyzed in the peripapillary region by mean blur rate as well as in the entire image area with a novel superpixel-based method. Relationships between measures were determined by Spearman correlation. Results Significant decreases in laser speckle blood flow were observed in both the retinal and choroidal vascular beds of irradiated, but not fellow, eyes. Overall, 24 of 25 patients had decreased blood flow compared to their fellow eye, including 5 of the 6 patients imaged within the first 6 months following brachytherapy. A significant negative correlation between blood flow and time from therapy was present. Conclusions Decreases in retinal and choroidal blood flow by laser speckle flowgraphy were detected within the first 6 months following brachytherapy. Reduced retinal and choroidal blood flow may be an early indicator of microangiographic response to radiation therapy.
- Published
- 2022
- Full Text
- View/download PDF
23. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient
- Author
-
Daniel N. Cagney, Shane Mesko, Diana D. Shi, Emil Lou, John Bryant, Supriya K. Jain, Hany Soliman, Arjun Sahgal, John P. Kirkpatrick, Eric Nesbit, Kristin A. Plichta, Cheng-Chia Wu, Steve Braunstein, Ashlyn S. Everett, Laurie E. Gaspar, Ryan Shanley, Drexell Hunter Boggs, Laura Masucci, Yi An, Jessica W. Lee, Ayal A. Aizer, Jing Li, William Sperduto, Paul D. Brown, Minesh P. Mehta, William G. Breen, Tim J. Kruser, Toshimichi Nakano, Hidefumi Aoyama, Veronica Chiang, Jill Remick, Paul W. Sperduto, John M. Buatti, Nan Lin, Tony J. C. Wang, Michael D. Chuong, Jason Chan, David Roberge, and Helen A. Shih
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Clinical Sciences ,Oncology and Carcinogenesis ,MEDLINE ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,Neoplasms ,Internal medicine ,Original Reports ,80 and over ,medicine ,Humans ,In patient ,Oncology & Carcinogenesis ,Karnofsky Performance Status ,Precision Medicine ,Cancer ,Aged ,Proportional Hazards Models ,Aged, 80 and over ,screening and diagnosis ,Brain Neoplasms ,business.industry ,Proportional hazards model ,Middle Aged ,Prognosis ,Precision medicine ,Brain Disorders ,Brain Cancer ,Clinical trial ,Detection ,030104 developmental biology ,Multicenter study ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Female ,Neoplasm Grading ,business ,4.2 Evaluation of markers and technologies - Abstract
PURPOSE Conventional wisdom has rendered patients with brain metastases ineligible for clinical trials for fear that poor survival could mask the benefit of otherwise promising treatments. Our group previously published the diagnosis-specific Graded Prognostic Assessment (GPA). Updates with larger contemporary cohorts using molecular markers and newly identified prognostic factors have been published. The purposes of this work are to present all the updated indices in a single report to guide treatment choice, stratify research, and define an eligibility quotient to expand eligibility. METHODS A multi-institutional database of 6,984 patients with newly diagnosed brain metastases underwent multivariable analyses of prognostic factors and treatments associated with survival for each primary site. Significant factors were used to define the updated GPA. GPAs of 4.0 and 0.0 correlate with the best and worst prognoses, respectively. RESULTS Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation ( P < .01) between subgroups. Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3-17 months, and 4-35 months, respectively. CONCLUSION Median survival varies widely and our ability to estimate survival for patients with brain metastases has improved. The updated GPA (available free at brainmetgpa.com) provides an accurate tool with which to estimate survival, individualize treatment, and stratify clinical trials. Instead of excluding patients with brain metastases, enrollment should be encouraged and those trials should be stratified by the GPA to ensure those trials make appropriate comparisons. Furthermore, we recommend the expansion of eligibility to allow for the enrollment of patients with previously treated brain metastases who have a 50% or greater probability of an additional year of survival (eligibility quotient > 0.50).
- Published
- 2020
- Full Text
- View/download PDF
24. Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today
- Author
-
Ashlyn S. Everett, Emil Lou, Drexell Hunter Boggs, Helen A. Shih, Jessica W. Lee, Laura Masucci, Diana D. Shi, Jason Chan, Paul W. Sperduto, Laurie E. Gaspar, Paul D. Brown, Minesh P. Mehta, Jing Li, William Sperduto, Jill Remick, David Roberge, John M. Buatti, Nan Lin, Shane Mesko, Ryan Shanley, Kristin A. Plichta, Tony J. C. Wang, William G. Breen, John P. Kirkpatrick, Arjun Sahgal, Toshimichi Nakano, Ayal A. Aizer, James B. Yu, Michael D. Chuong, Supriya K. Jain, Hany Soliman, Veronica Chiang, John Bryant, Daniel N. Cagney, Hidefumi Aoyama, Cheng-Chia Wu, Tim J. Kruser, Steve Braunstein, and Eric Nesbit
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Clinical Sciences ,Oncology and Carcinogenesis ,Breast Neoplasms ,Article ,030218 nuclear medicine & medical imaging ,Retrospective database ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,Breast cancer ,Clinical Research ,Internal medicine ,Breast Cancer ,80 and over ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Oncology & Carcinogenesis ,Survival analysis ,Cancer ,Aged ,Retrospective Studies ,Aged, 80 and over ,Radiation ,BRCA1 Protein ,Brain Neoplasms ,business.industry ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Other Physical Sciences ,Clinical trial ,Tumor Subtype ,030220 oncology & carcinogenesis ,Cohort ,Female ,business ,Median survival - Abstract
PurposeBrain metastases are a common sequelae of breast cancer. Survival varies widely based on diagnosis-specific prognostic factors (PF). We previously published a prognostic index (Graded Prognostic Assessment [GPA]) for patients with breast cancer with brain metastases (BCBM), based on cohort A (1985-2007, n = 642), then updated it, reporting the effect of tumor subtype in cohort B (1993-2010, n = 400). The purpose of this study is to update the Breast GPA with a larger contemporary cohort (C) and compare treatment and survival across the 3 cohorts.Methods and materialsA multi-institutional (19), multinational (3), retrospective database of 2473 patients with breast cancer with newly diagnosed brain metastases (BCBM) diagnosed from January 1, 2006, to December 31, 2017, was created and compared with prior cohorts. Associations of PF and treatment with survival were analyzed. Kaplan-Meier survival estimates were compared with log-rank tests. PF were weighted and the Breast GPA was updated such that a GPA of 0 and 4.0 correlate with the worst and best prognoses, respectively.ResultsMedian survival (MS) for cohorts A, B, and C improved over time (from 11, to 14 to 16 months, respectively; P < .01), despite the subtype distribution becoming less favorable. PF significant for survival were tumor subtype, Karnofsky Performance Status, age, number of BCBMs, and extracranial metastases (all P < .01). MS for GPA 0 to 1.0, 1.5-2.0, 2.5-3.0, and 3.5-4.0 was 6, 13, 24, and 36 months, respectively. Between cohorts B and C, the proportion of human epidermal receptor 2 + subtype decreased from 31% to 18% (P < .01) and MS in this subtype increased from 18 to 25 months (P < .01).ConclusionsMS has improved modestly but varies widely by diagnosis-specific PF. New PF are identified and incorporated into an updated Breast GPA (free online calculator available at brainmetgpa.com). The Breast GPA facilitates clinical decision-making and will be useful for stratification of future clinical trials. Furthermore, these data suggest human epidermal receptor 2-targeted therapies improve clinical outcomes in some patients with BCBM.
- Published
- 2020
- Full Text
- View/download PDF
25. Multisite Technical and Clinical Performance Evaluation of Quantitative Imaging Biomarkers from 3D FDG PET Segmentations of Head and Neck Cancer Images
- Author
-
Binsheng Zhao, Milan Grkovski, Charles M. Laymon, John Sunderland, Ghassan Hamarneh, Dmitry B. Goldgof, Brian J. Smith, Sadek Nehmeh, John P. Muzi, Reinhard Beichel, Payam Ahmadvand, Matthew J. Oborski, Mark Muzi, Ethan J. Ulrich, Christian Bauer, Robert J. Gillies, James M. Mountz, Mikalai M. Budzevich, Paul E. Kinahan, and John M. Buatti
- Subjects
Computer science ,Bayesian probability ,Image processing ,Standardized uptake value ,Fluorodeoxyglucose F18 ,Robustness (computer science) ,Biomarkers, Tumor ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Segmentation ,Research Articles ,Reproducibility ,medicine.diagnostic_test ,business.industry ,segmentation ,Head and neck cancer ,Reproducibility of Results ,Bayes Theorem ,Pattern recognition ,medicine.disease ,multi-site performance analysis ,Head and Neck Neoplasms ,radiomics ,Positron emission tomography ,Positron-Emission Tomography ,FDG PET ,head and neck cancer ,Artificial intelligence ,Tomography, X-Ray Computed ,business - Abstract
Quantitative imaging biomarkers (QIBs) provide medical image–derived intensity, texture, shape, and size features that may help characterize cancerous tumors and predict clinical outcomes. Successful clinical translation of QIBs depends on the robustness of their measurements. Biomarkers derived from positron emission tomography images are prone to measurement errors owing to differences in image processing factors such as the tumor segmentation method used to define volumes of interest over which to calculate QIBs. We illustrate a new Bayesian statistical approach to characterize the robustness of QIBs to different processing factors. Study data consist of 22 QIBs measured on 47 head and neck tumors in 10 positron emission tomography/computed tomography scans segmented manually and with semiautomated methods used by 7 institutional members of the NCI Quantitative Imaging Network. QIB performance is estimated and compared across institutions with respect to measurement errors and power to recover statistical associations with clinical outcomes. Analysis findings summarize the performance impact of different segmentation methods used by Quantitative Imaging Network members. Robustness of some advanced biomarkers was found to be similar to conventional markers, such as maximum standardized uptake value. Such similarities support current pursuits to better characterize disease and predict outcomes by developing QIBs that use more imaging information and are robust to different processing factors. Nevertheless, to ensure reproducibility of QIB measurements and measures of association with clinical outcomes, errors owing to segmentation methods need to be reduced.
- Published
- 2020
- Full Text
- View/download PDF
26. Impact of Treatment Time on Outcome for Resected Head and Neck Squamous Cell Carcinoma by HPV Status
- Author
-
John M. Watkins, Anthony N. Snow, Carryn M. Anderson, John M. Buatti, Nicholas S. Andresen, Nitin A. Pagedar, Rodrigo Bayon, and Sarah L. Mott
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Disease ,medicine.disease ,Head and neck squamous-cell carcinoma ,Resection ,Radiation therapy ,Internal medicine ,General Earth and Planetary Sciences ,Medicine ,Treatment time ,Human papillomavirus ,Inverse correlation ,business ,Hpv status ,General Environmental Science - Abstract
Background and Purpose: Prior investigations have demonstrated an inverse correlation between the interval from resection of head and neck squamous cell carcinoma (HNSCC) to radiotherapy (RT) completion (overall treatment time; OTT) and disease control. However, the importance of OTT in human papillomavirus (HPV)-associated HNSCC remains to be determined. This study evaluates whether OTT remains independently associated with cancer control when evaluated by HPV association. Material and Methods: The data of HNSCC patients treated with curative-intent surgical resection followed by RT were collected. Univariable and multivariable analyses were used to assess the effects of HPV association and OTT. Results: From 2002-2014, 73 eligible patients were identified (36 HPV-associated). The median OTT was 94 days (range, 69-185, with no difference between HPV subgroups). At a median follow-up of 34.9 months (range, 2.6-162.2), 21 patients experienced disease failure, and 25 died. HPV-association was linked to improved disease-free survival (DFS), disease-specific survival (DFS), and overall survival (OS) by univariable and multivariable analyses. OTT was associated with improved DFS by univariable and multivariable analyses. Conclusion: OTT remains significantly associated with cancer control in the setting of HPV-associated disease. Efforts should be made to minimize the delay between resection and completion of RT for all HNSCC patients.
- Published
- 2020
- Full Text
- View/download PDF
27. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival
- Author
-
David Roberge, Jing Li, Steve Braunstein, Drexell Hunter Boggs, Laurie E. Gaspar, Emil Lou, Supriya K. Jain, Jessica W. Lee, Hany Soliman, Laura Masucci, Jill Remick, Arjun Sahgal, John P. Kirkpatrick, William Sperduto, William G. Breen, Jason Chan, Toshimichi Nakano, Diana D. Shi, Paul D. Brown, James B. Yu, Minesh P. Mehta, Helen A. Shih, Veronica Chiang, Paul W. Sperduto, John M. Buatti, Daniel N. Cagney, Kristin A. Plichta, Nan Lin, Michael D. Chuong, Tim J. Kruser, Eric Nesbit, Ashlyn S. Everett, Ryan Shanley, Shane Mesko, Cheng-Chia Wu, Ayal A. Aizer, Hidefumi Aoyama, John Bryant, and Tony J. C. Wang
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Receptor Status ,Receptor, ErbB-2 ,medicine.drug_class ,Clinical Trials and Supportive Activities ,Oncology and Carcinogenesis ,Clinical Investigations ,Estrogen receptor ,Breast Neoplasms ,Metastasis ,breast cancer ,ErbB-2 ,Breast cancer ,Clinical Research ,brain metastases ,Internal medicine ,Receptors ,Biomarkers, Tumor ,2.1 Biological and endogenous factors ,Humans ,Medicine ,Oncology & Carcinogenesis ,Aetiology ,Receptor ,Progesterone ,Cancer ,Retrospective Studies ,Tumor ,Brain Neoplasms ,business.industry ,Neurosciences ,Estrogens ,medicine.disease ,Primary tumor ,Good Health and Well Being ,Estrogen ,Hormone receptor ,estrogen/progesterone/HER2 receptor discordance ,Neurology (clinical) ,Receptors, Progesterone ,business ,Biomarkers - Abstract
Background Breast cancer treatment is based on estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2). At the time of metastasis, receptor status can be discordant from that at initial diagnosis. The purpose of this study was to determine the incidence of discordance and its effect on survival and subsequent treatment in patients with breast cancer brain metastases (BCBM). Methods A retrospective database of 316 patients who underwent craniotomy for BCBM between 2006 and 2017 was created. Discordance was considered present if the ER, PR, or HER2 status differed between the primary tumor and the BCBM. Results The overall receptor discordance rate was 132/316 (42%), and the subtype discordance rate was 100/316 (32%). Hormone receptors (HR, either ER or PR) were gained in 40/160 (25%) patients with HR-negative primary tumors. HER2 was gained in 22/173 (13%) patients with HER2-negative primary tumors. Subsequent treatment was not adjusted for most patients who gained receptors—nonetheless, median survival (MS) improved but did not reach statistical significance (HR, 17–28 mo, P = 0.12; HER2, 15–19 mo, P = 0.39). MS for patients who lost receptors was worse (HR, 27–18 mo, P = 0.02; HER2, 30–18 mo, P = 0.08). Conclusions Receptor discordance between primary tumor and BCBM is common, adversely affects survival if receptors are lost, and represents a missed opportunity for use of effective treatments if receptors are gained. Receptor analysis of BCBM is indicated when clinically appropriate. Treatment should be adjusted accordingly. Key Points 1. Receptor discordance alters subtype in 32% of BCBM patients. 2. The frequency of receptor gain for HR and HER2 was 25% and 13%, respectively. 3. If receptors are lost, survival suffers. If receptors are gained, consider targeted treatment.
- Published
- 2020
- Full Text
- View/download PDF
28. Reduced blood flow by laser speckle flowgraphy after
- Author
-
Michelle R, Tamplin, Jui-Kai, Wang, Anthony H, Vitale, Ryuya, Hashimoto, Mona K, Garvin, Elaine M, Binkley, Daniel E, Hyer, John M, Buatti, H Culver, Boldt, Randy H, Kardon, and Isabella M, Grumbach
- Subjects
Iodine Radioisotopes ,Uveal Neoplasms ,Cross-Sectional Studies ,Choroid ,Lasers ,Brachytherapy ,Laser-Doppler Flowmetry ,Humans ,Melanoma ,Blood Flow Velocity - Abstract
To determine whether reductions in retinal and choroidal blood flow measured by laser speckle flowgraphy are detected afterIn a cross-sectional study, retinal and choroidal blood flow were measured using laser speckle flowgraphy in 25 patients after treatment withSignificant decreases in laser speckle blood flow were observed in both the retinal and choroidal vascular beds of irradiated, but not fellow, eyes. Overall, 24 of 25 patients had decreased blood flow compared to their fellow eye, including 5 of the 6 patients imaged within the first 6 months following brachytherapy. A significant negative correlation between blood flow and time from therapy was present.Decreases in retinal and choroidal blood flow by laser speckle flowgraphy were detected within the first 6 months following brachytherapy. Reduced retinal and choroidal blood flow may be an early indicator of microangiographic response to radiation therapy.
- Published
- 2022
29. Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer
- Author
-
Muhammad Furqan, Taher Abu-Hejleh, Laura M. Stephens, Stacey M. Hartwig, Sarah L. Mott, Casey F. Pulliam, Michael Petronek, John B. Henrich, Melissa A. Fath, Jon C. Houtman, Steven M. Varga, Kellie L. Bodeker, Aaron D. Bossler, Andrew M. Bellizzi, Jun Zhang, Varun Monga, Hariharasudan Mani, Marina Ivanovic, Brian J. Smith, Margaret M. Byrne, William Zeitler, Brett A. Wagner, Garry R. Buettner, Joseph J. Cullen, John M. Buatti, Douglas R. Spitz, and Bryan G. Allen
- Subjects
Lung Neoplasms ,Paclitaxel ,Carcinoma, Non-Small-Cell Lung ,Organic Chemistry ,Clinical Biochemistry ,Antineoplastic Combined Chemotherapy Protocols ,Leukocytes, Mononuclear ,Humans ,Biochemistry ,Carboplatin ,Platinum - Abstract
Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration. Pre-clinical studies have reported that pharmacological ascorbate (P-AscH-) enhances NSCLC response to platinum-based therapy. We conducted a phase II clinical trial combining P-AscH- with carboplatin-paclitaxel chemotherapy.Chemotherapy naïve advanced stage NSCLC patients received 75 g ascorbate twice per week intravenously with carboplatin and paclitaxel every three weeks for four cycles. The primary endpoint was to improve tumor response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 compared to the historical control of 20%. The trial was conducted as an optimal Simon's two-stage design. Blood samples were collected for exploratory analyses.The study enrolled 38 patients and met its primary endpoint with an objective response rate of 34.2% (p = 0.03). All were confirmed partial responses (cPR). The disease control rate was 84.2% (stable disease + cPR). Median progression-free and overall survival were 5.7 months and 12.8 months, respectively. Treatment-related adverse events (TRAE) included one grade 5 (neutropenic fever) and five grade 4 events (cytopenias). Cytokine and chemokine data suggest that the combination elicits an immune response. Immunophenotyping of peripheral blood mononuclear cells demonstrated an increase in effector CD8 T-cells in patients with a progression-free survival (PFS) ≥ 6 months.The addition of P-AscH- to platinum-based chemotherapy improved tumor response in advanced stage NSCLC. P-AscH- appears to alter the host immune response and needs further investigation as a potential adjuvant to immunotherapy.
- Published
- 2022
30. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors
- Author
-
Paul W. Sperduto, Brian De, Jing Li, David Carpenter, John Kirkpatrick, Michael Milligan, Helen A. Shih, Tugce Kutuk, Rupesh Kotecha, Hajime Higaki, Manami Otsuka, Hidefumi Aoyama, Malie Bourgoin, David Roberge, Salah Dajani, Sean Sachdev, Jordan Gainey, John M. Buatti, William Breen, Paul D. Brown, Lisa Ni, Steve Braunstein, Matthew Gallitto, Tony J.C. Wang, Ryan Shanley, Emil Lou, Jay Shiao, Laurie E. Gaspar, Satoshi Tanabe, Toshimichi Nakano, Yi An, Veronica Chiang, Liang Zeng, Hany Soliman, Hesham Elhalawani, Daniel Cagney, Evan Thomas, Drexell H. Boggs, Manmeet S. Ahluwalia, and Minesh P. Mehta
- Subjects
Cancer Research ,Radiation ,Lung Neoplasms ,Brain Neoplasms ,Adenocarcinoma of Lung ,Adenocarcinoma ,Prognosis ,Small Cell Lung Carcinoma ,B7-H1 Antigen ,ErbB Receptors ,Oncology ,Carcinoma, Non-Small-Cell Lung ,Humans ,Radiology, Nuclear Medicine and imaging ,Anaplastic Lymphoma Kinase ,Retrospective Studies - Abstract
Patients with lung cancer and brain metastases represent a markedly heterogeneous population. Accurate prognosis is essential to optimally individualize care. In prior publications, we described the graded prognostic assessment (GPA), but a GPA for patients with small cell lung cancer (SCLC) has never been reported, and in non-small cell lung cancer (NSCLC), the effect of programmed death ligand 1 (PD-L1) was unknown. The 3-fold purpose of this work is to provide the initial report of an SCLC GPA, to evaluate the effect of PD-L1 on survival in patients with NSCLC, and to update the Lung GPA accordingly.A multivariable analysis of prognostic factors and treatments associated with survival was performed on 4183 patients with lung cancer (3002 adenocarcinoma, 611 nonadenocarcinoma, 570 SCLC) with newly diagnosed brain metastases between January 1, 2015, and December 31, 2020, using a multi-institutional retrospective database. Significant variables were used to update the Lung GPA.Overall median survival for lung adenocarcinoma, SCLC, and nonadenocarcinoma was 17, 10, and 8 months, respectively, but varied widely by GPA from 2 to 52 months. In SCLC, the significant prognostic factors were age, performance status, extracranial metastases, and number of brain metastases. In NSCLC, the distribution of molecular markers among patients with lung adenocarcinoma and known primary tumor molecular status revealed alterations/expression in PD-L1 50% to 100%, PD-L1 1% to 49%, epidermal growth factor receptor, and anaplastic lymphoma kinase in 32%, 31%, 30%, and 7%, respectively. Median survival of patients with lung adenocarcinoma and brain metastases with 0, 1% to 49%, and ≥50% PD-L1 expression was 17, 19, and 24 months, respectively (P.01), confirming PD-L1 is a prognostic factor. Previously identified prognostic factors for NSCLC (epidermal growth factor receptor and anaplastic lymphoma kinase status, performance status, age, number of brain metastases, and extracranial metastases) were reaffirmed. These factors were incorporated into the updated Lung GPA with robust separation between subgroups for all histologies.Survival for patients with lung cancer and brain metastases has improved but varies widely. The initial report of a GPA for SCLC is presented. For patients with NSCLC-adenocarcinoma and brain metastases, PD-L1 is a newly identified significant prognostic factor, and the previously identified factors were reaffirmed. The updated indices establish unique criteria for SCLC, NSCLC-nonadenocarcinoma, and NSCLC-adenocarcinoma (incorporating PD-L1). The updated Lung GPA, available for free at brainmetgpa.com, provides an accurate tool to estimate survival, individualize treatment, and stratify clinical trials.
- Published
- 2021
31. Quantitative Imaging in Radiation Treatment Planning
- Author
-
John M. Buatti and Reinhard Beichel
- Subjects
medicine.medical_specialty ,Quantitative imaging ,business.industry ,Medicine ,Medical physics ,business ,Radiation treatment planning - Abstract
Radiation therapy (RT), along with surgery and medical therapies, are the fundamental methods used to treat cancers, as well as a wide range of other diseases. RT is delivered in multiple forms, including external beam therapy, brachytherapy, and radiopharmaceutical therapy. RT is a completely image-guided treatment paradigm, and benefits from advances made in quantitative imaging (QI). The therapeutic effects of radiation are proven, and have improved with each advance, enabling more precisely delivered radiation dose to a tumor target and avoidance of normal tissues. Advances in QI enable improved target and normal tissue definitions, and advances in computer-based algorithmic tools enable enhanced consistency, efficiency, and depth in utilization of the rich information within QI. RT benefits from application of these enhanced tools to imaging to ultimately improve therapy.
- Published
- 2021
- Full Text
- View/download PDF
32. A Recursive Partitioning Analysis Demonstrating Risk Subsets for 8-Year Biochemical Relapse After Margin-Positive Radical Prostatectomy Without Adjuvant Hormone or Radiation Therapy
- Author
-
Steven N. Seyedin, Joseph M. Caster, Chad R. Tracy, John M. Watkins, J. Kyle Russo, Zachary Mayo, Anthony N. Snow, Michael Laszewski, John M. Buatti, Mark C. Smith, and Sarah L. Mott
- Subjects
medicine.medical_specialty ,business.industry ,Prostatectomy ,medicine.medical_treatment ,Urology ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Retrospective cohort study ,Recursive partitioning ,medicine.disease ,Radiation therapy ,Prostate cancer ,Medical physics. Medical radiology. Nuclear medicine ,Oncology ,PSA Failure ,Clinical endpoint ,Medicine ,Radiology, Nuclear Medicine and imaging ,Scientific Article ,Hormone therapy ,business ,RC254-282 - Abstract
Purpose The cohort of patients with locally advanced prostate cancer (PC) and positive surgical margin(s) at radical prostatectomy (RP) who would benefit from salvage or adjuvant treatment is unclear. This study examines the risk of prostate-specific antigen (PSA) relapse in a large population of men with PC after margin-positive RP. Methods and Materials Using a multi-institutional database, patients with clinically localized PC who underwent RP between 2002 and 2010 with recorded follow-up PSA were retrospectively selected. Patients were excluded for pathologic seminal vesicle or lymph node involvement, metastatic disease, pre-RP PSA ≥ 30, or adjuvant (nonsalvage) radiation therapy or hormone therapy. The primary endpoint was biochemical relapse free survival (bRFS), where PSA failure was defined as PSA > 0.10 ng/mL and rising, or at salvage intervention. The Kaplan-Meier method was employed for bRFS estimates; recursive partitioning analysis using cumulative or single maximal margin extent (ME) and Gleason grade (GG) at RP was applied to identify variables associated with bRFS. Results At median follow-up of 105 months, 210 patients with positive margins at RP were eligible for analysis, and 89 had experienced PSA relapse. Median age was 61 years (range, 43-76), and median pre-RP PSA 5.8 ng/mL (1.6-26.0). Recursive partitioning analysis yielded 5 discrete risk groups, with the lowest risk group (GG1, ≤ 2 mm ME) demonstrating a bRFS of 92% at 8 years compared with the highest risk group (GG3-5, ≥ 3 mm ME) of 11%. Conclusions This retrospective study suggests that it may be possible to risk-stratify patients undergoing margin-positive RP using commonly acquired clinical and pathologic variables. Patients with low-grade tumors and minimally involved margins have a very low recurrence risk and may be able to forego postprostatectomy radiation. Meanwhile, those with higher grade and greater involvement could benefit from adjuvant or early salvage radiation therapy.
- Published
- 2021
33. Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury
- Author
-
Robert A. Beardsley, Kranti A. Mapuskar, Dennis P. Riley, Emily J. Steinbach, Keene Jeffery L, Amira Zaher, Jon Holmlund, Douglas R. Spitz, Diana Zepeda-Orozco, Bryan G. Allen, John M. Buatti, and Carryn M. Anderson
- Subjects
mitochondrial metabolism ,Physiology ,Clinical Biochemistry ,Renal function ,cisplatin ,Review ,RM1-950 ,Pharmacology ,urologic and male genital diseases ,Biochemistry ,Nephrotoxicity ,Superoxide dismutase ,chemistry.chemical_compound ,medicine ,Molecular Biology ,Cisplatin ,chemistry.chemical_classification ,reactive oxygen species ,Reactive oxygen species ,biology ,business.industry ,Superoxide ,Acute kidney injury ,Cell Biology ,medicine.disease ,superoxide dismutase ,female genital diseases and pregnancy complications ,mitochondria ,acute kidney injury ,chemistry ,biology.protein ,superoxide ,Therapeutics. Pharmacology ,business ,chronic kidney disease ,medicine.drug ,Kidney disease - Abstract
Cisplatin is a chemotherapy agent commonly used to treat a wide variety of cancers. Despite the potential for both severe acute and chronic side effects, it remains a preferred therapeutic option for many malignancies due to its potent anti-tumor activity. Common cisplatin-associated side-effects include acute kidney injury (AKI) and chronic kidney disease (CKD). These renal injuries may cause delays and potentially cessation of cisplatin therapy and have long-term effects on renal function reserve. Thus, developing mechanism-based interventional strategies that minimize cisplatin-associated kidney injury without reducing efficacy would be of great benefit. In addition to its action of cross-linking DNA, cisplatin has been shown to affect mitochondrial metabolism, resulting in mitochondrially derived reactive oxygen species (ROS). Increased ROS formation in renal proximal convoluted tubule cells is associated with cisplatin-induced AKI and CKD. We review the mechanisms by which cisplatin may induce AKI and CKD and discuss the potential of mitochondrial superoxide dismutase mimetics to prevent platinum-associated nephrotoxicity.
- Published
- 2021
34. Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
- Author
-
Philip Kovoor, Stephen T. Sonis, Kyle Colvett, Jeffrey Mark Brill, Madhur Garg, Neal Dunlap, James Wheeler, Roberto Arevalo-Araujo, Sharon M. Gordon, Francis P. Worden, Abhinand V. Peddada, Matthew Downs, Voichita Bar-Ad, Marcelo Bonomi, Anshu K. Jain, Christopher M. Lee, John M. Buatti, Chaitali Singh Nangia, Carryn M. Anderson, Deborah P. Saunders, Sanford Katz, Jon Holmlund, Amarinthia Curtis, Dukagjin Blakaj, Arielle S. Lee, Sanjiv S. Agarwala, and Douglas C. Miller
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Time Factors ,medicine.medical_treatment ,Severity of Illness Index ,Gastroenterology ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,Risk Factors ,law ,Aged, 80 and over ,Ontario ,Incidence ,Chemoradiotherapy ,ORIGINAL REPORTS ,Middle Aged ,Head and Neck Cancer ,Oropharyngeal Neoplasms ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Female ,Mouth Neoplasms ,medicine.drug ,Adult ,medicine.medical_specialty ,Antineoplastic Agents ,Radiation-Protective Agents ,Placebo ,03 medical and health sciences ,Double-Blind Method ,Internal medicine ,Organometallic Compounds ,medicine ,Mucositis ,Humans ,Radiation Injuries ,Aged ,Cisplatin ,Stomatitis ,business.industry ,Head and neck cancer ,Chemoradiotherapy, Adjuvant ,medicine.disease ,United States ,Radiation therapy ,Clinical trial ,030104 developmental biology ,Radiotherapy, Intensity-Modulated ,business - Abstract
PURPOSE Oral mucositis (OM) remains a common, debilitating toxicity of radiation therapy (RT) for head and neck cancer. The goal of this phase IIb, multi-institutional, randomized, double-blind trial was to compare the efficacy and safety of GC4419, a superoxide dismutase mimetic, with placebo to reduce the duration, incidence, and severity of severe OM (SOM). PATIENTS AND METHODS A total of 223 patients (from 44 institutions) with locally advanced oral cavity or oropharynx cancer planned to be treated with definitive or postoperative intensity-modulated RT (IMRT; 60 to 72 Gy [≥ 50 Gy to two or more oral sites]) plus cisplatin (weekly or every 3 weeks) were randomly assigned to receive 30 mg (n = 73) or 90 mg (n = 76) of GC4419 or to receive placebo (n = 74) by 60-minute intravenous administration before each IMRT fraction. WHO grade of OM was assessed biweekly during IMRT and then weekly for up to 8 weeks after IMRT. The primary endpoint was duration of SOM tested for each active dose level versus placebo (intent-to-treat population, two-sided α of .05). The National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03, was used for adverse event grading. RESULTS Baseline patient and tumor characteristics as well as treatment delivery were balanced. With 90 mg GC4419 versus placebo, SOM duration was significantly reduced ( P = .024; median, 1.5 v 19 days). SOM incidence (43% v 65%; P = .009) and severity (grade 4 incidence, 16% v 30%; P = .045) also were improved. Intermediate improvements were seen with the 30-mg dose. Safety was comparable across arms, with no significant GC4419-specific toxicity nor increase of known toxicities of IMRT plus cisplatin. The 2-year follow-up for tumor outcomes is ongoing. CONCLUSION GC4419 at a dose of 90 mg produced a significant, clinically meaningful reduction of SOM duration, incidence, and severity with acceptable safety. A phase III trial (ROMAN; ClinicalTrials.gov identifier: NCT03689712 ) has begun.
- Published
- 2019
- Full Text
- View/download PDF
35. Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA)
- Author
-
Hirotake Saito, Laura Masucci, Natalie A. Lockney, Emil Lou, Sten Myrehaug, John P. Kirkpatrick, Daniel D. Tandberg, Paul W. Sperduto, Arjun Sahgal, Ayal A. Aizer, William G. Breen, Diana D. Shi, Kathryn Beal, John M. Buatti, Hidefumi Aoyama, James B. Yu, J.K. Molitoris, Tony J. C. Wang, Ryan Shanley, Laurie E. Gaspar, Albert Attia, Helen A. Shih, Veronica Chiang, David Roberge, Penny K. Sneed, Jing Li, Cheng-Chia Wu, Brent D. Cameron, Jessica Parkhurst, Michael D. Chuong, Daniel N. Cagney, Paul D. Brown, Minesh P. Mehta, Steve Braunstein, Penny Fang, and Supriya Jain
- Subjects
Oncology ,medicine.medical_specialty ,R895-920 ,macromolecular substances ,Article ,030218 nuclear medicine & medical imaging ,Medical physics. Medical radiology. Nuclear medicine ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,stomatognathic system ,Clinical Research ,Internal medicine ,parasitic diseases ,Medicine ,Radiology, Nuclear Medicine and imaging ,In patient ,RC254-282 ,Cancer ,business.industry ,Proportional hazards model ,Hazard ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Brain metastases ,social sciences ,Prognosis ,Brain Disorders ,Gastrointestinal cancers ,3. Good health ,Clinical trial ,030220 oncology & carcinogenesis ,Cohort ,population characteristics ,Prognostic group ,Digestive Diseases ,business ,human activities ,Gi cancer ,Median survival ,End-of-life - Abstract
Highlights • Brain metastases in GI cancer patients are not uncommon. • Survival varies widely within this cohort. • New identified prognostic factors are incorporated in an updated prognostic index. • This index, the GI-GPA, will better estimate survival. • The GI-GPA is useful in treatment selection and stratification of clinical trials., Background Patients with gastrointestinal cancers and brain metastases (BM) represent a unique and heterogeneous population. Our group previously published the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with GI cancers (GI-GPA) (1985–2007, n = 209). The purpose of this study is to update the GI-GPA based on a larger contemporary database. Methods An IRB-approved consortium database analysis was performed using a multi-institutional (18), multi-national (3) cohort of 792 patients with gastrointestinal (GI) cancers, with newly-diagnosed BM diagnosed between 1/1/2006 and 12/31/2017. Survival was measured from date of first treatment for BM. Multiple Cox regression was used to select and weight prognostic factors in proportion to their hazard ratios. These factors were incorporated into the updated GI-GPA. Results Median survival (MS) varied widely by primary site and other prognostic factors. Four significant factors (KPS, age, extracranial metastases and number of BM) were used to formulate the updated GI-GPA. Overall MS for this cohort remains poor; 8 months. MS by GPA was 3, 7, 11 and 17 months for GPA 0–1, 1.5–2, 2.5–3.0 and 3.5–4.0, respectively. >30% present in the worst prognostic group (GI-GPA of ≤1.0). Conclusions Brain metastases are not uncommon in GI cancer patients and MS varies widely among them. This updated GI-GPA index improves our ability to estimate survival for these patients and will be useful for therapy selection, end-of-life decision-making and stratification for future clinical trials. A user-friendly, free, on-line app to calculate the GPA score and estimate survival for an individual patient is available at brainmetgpa.com.
- Published
- 2019
- Full Text
- View/download PDF
36. Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas
- Author
-
Kellie L. Bodeker, Timothy Ginader, John M. Buatti, Kripa Guram, Darrin Pelland, Edward C. Pennington, and Mark C. Smith
- Subjects
medicine.medical_specialty ,business.industry ,Standard treatment ,medicine.medical_treatment ,Cancer ,Retrospective cohort study ,medicine.disease ,030218 nuclear medicine & medical imaging ,Radiation therapy ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Glioma ,medicine ,symbols ,Population study ,Radiology, Nuclear Medicine and imaging ,Radiology ,business ,Survival rate ,Fisher's exact test - Abstract
Purpose The number of studies that evaluate treatment margins for high grade gliomas (HGG) are limited. We hypothesize that patients with HGG who are treated with a gross tumor volume (GTV) to planning tumor volume (PTV) expansion of ≤1 cm will have progression-free survival (PFS) and overall survival (OS) rates similar to those treated in accordance with standard protocols by the Radiation Therapy Oncology Group or European Organisation for Research and Treatment of Cancer. Furthermore, the PFS and OS of subgroups within the study population will have equivalent survival outcomes with GTV1-to-PTV1 margins of 1.0 cm and 0.4 cm. Methods and materials Treatment plans and outcomes for patients with pathologically confirmed HGG were analyzed (n = 267). Survival (PFS and OS) was calculated from the time of the first radiation treatment and a χ2 test or Fisher exact test was used to calculate the associations between margin size and patient characteristics. Survival was estimated using Kaplan-Meier and compared using the log-rank test. All analyses were performed on the univariate level. Results The median PFS and OS times were 10.6 and 19.1 months, respectively. By disease, the median PFS and OS times were 8.6 and 16.1 months for glioblastoma and 26.7 and 52.5 months for anaplastic glioma. The median follow-up time was 18.3 months. The treatment margin had no effect on outcome and the 1.0 cm GTV1-PTV1 margin subgroup (n = 212) showed median PFS and OS times of 10.7 and 19.1 months, respectively, and the 0.4 cm margin subgroup (n = 55) 10.2 and 19.3 months, respectively. In comparison with the standard treatment with 2 cm to 3 cm margins, there was not a significant difference in outcomes. Conclusions There is no apparent difference in survival when utilizing smaller versus larger margins as defined by the guidelines of the Radiation Therapy Oncology Group and European Organisation for Research and Treatment of Cancer. Although there remains no class I evidence that outcomes after treatment with smaller margins are identical to those after treatment with larger margins, this large series with long-term follow up suggests that a reduction of the margins is safe and further investigation is warranted.
- Published
- 2019
- Full Text
- View/download PDF
37. FLT PET Radiomics for Response Prediction to Chemoradiation Therapy in Head and Neck Squamous Cell Cancer
- Author
-
Carryn M. Anderson, Michael M. Graham, Laura L. Boles Ponto, Reinhard Beichel, Yusuf Menda, John M. Buatti, Ethan J. Ulrich, John Sunderland, and Brian J. Smith
- Subjects
Adult ,Male ,medicine.medical_specialty ,FLT ,030218 nuclear medicine & medical imaging ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Radiomics ,Image Interpretation, Computer-Assisted ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Research Articles ,Aged ,Neoplasm Staging ,Observer Variation ,medicine.diagnostic_test ,business.industry ,Proportional hazards model ,Squamous Cell Carcinoma of Head and Neck ,Head and neck cancer ,prediction ,Chemoradiotherapy ,Middle Aged ,medicine.disease ,Prognosis ,Primary tumor ,Dideoxynucleosides ,3. Good health ,medicine.anatomical_structure ,PET ,Treatment Outcome ,Positron emission tomography ,radiomics ,head and neck cancer ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Positron-Emission Tomography ,Multiple comparisons problem ,Female ,Radiology ,Bone marrow ,medicine.symptom ,Radiopharmaceuticals ,business - Abstract
Radiomics is an image analysis approach for extracting large amounts of quantitative information from medical images using a variety of computational methods. Our goal was to evaluate the utility of radiomic feature analysis from 18F-fluorothymidine positron emission tomography (FLT PET) obtained at baseline in prediction of treatment response in patients with head and neck cancer. Thirty patients with advanced-stage oropharyngeal or laryngeal cancer, treated with definitive chemoradiation therapy, underwent FLT PET imaging before treatment. In total, 377 radiomic features of FLT uptake and feature variants were extracted from volumes of interest, these features variants were defined by either the primary tumor or the total lesion burden, which consisted of the primary tumor and all FLT-avid nodes. Feature variants included normalized measurements of uptake, which were calculated by dividing lesion uptake values by the mean uptake value in the bone marrow. Feature reduction was performed using clustering to remove redundancy, leaving 172 representative features. Effects of these features on progression-free survival were modeled with Cox regression and P-values corrected for multiple comparisons. In total, 9 features were considered significant. Our results suggest that smaller, more homogenous lesions at baseline were associated with better prognosis. In addition, features extracted from total lesion burden had a higher concordance index than primary tumor features for 8 of the 9 significant features. Furthermore, total lesion burden features showed lower interobserver variability.
- Published
- 2019
38. Ketogenic Diet with Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma: Preclinical and Phase 1 Trial Results
- Author
-
Elizabeth Loth, Carryn M. Anderson, Douglas R. Spitz, Samuel N. Rodman, Daniel C. Ma, Melissa A. Fath, Andrew B. Davis, Logan Ahmann, Visarut Buranasudja, Kellie L. Bodeker, Michael L. McCormick, Andrean L. Simons, Wenqing Sun, Bryan G. Allen, Jessica Parkhurst, Kayla R. Follmer, and John M. Buatti
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Racemases and Epimerases ,Biophysics ,Phases of clinical research ,Gastroenterology ,Article ,Mice ,Stress, Physiological ,Radiation, Ionizing ,Internal medicine ,medicine ,Animals ,Humans ,Radiology, Nuclear Medicine and imaging ,Enoyl-CoA Hydratase ,Aged ,Chemotherapy ,Radiation ,Squamous Cell Carcinoma of Head and Neck ,business.industry ,Head and neck cancer ,3-Hydroxyacyl CoA Dehydrogenases ,Cancer ,Chemoradiotherapy ,Middle Aged ,Acetyl-CoA C-Acyltransferase ,Carbon-Carbon Double Bond Isomerases ,medicine.disease ,Head and neck squamous-cell carcinoma ,Mitochondria ,Radiation therapy ,Oxidative Stress ,Tolerability ,Heterografts ,Female ,Diet, Ketogenic ,business ,Ketogenic diet - Abstract
Ketogenic diets (KD) are high in fat and low in carbohydrates, forcing cells to utilize mitochondrial fatty acid oxidation for energy production. Since cancer cells demonstrate increased mitochondrial oxidative stress relative to normal cells, we hypothesized that a KD may selectively enhance metabolic oxidative stress in head and neck cancer cells, sensitizing them to radiation and platinum-based chemotherapy without causing increased toxicity in surrounding normal tissues. This hypothesis was tested in preclinical murine xenografts and in a phase 1 clinical trial (NCT01975766). In this study, mice bearing human head and neck cancer xenografts (FaDu) were fed either standard mouse chow or KetoCal® KD (90% fat, 8% carbohydrate, 2% protein) and exposed to ionizing radiation. Tumors were harvested from mice to test for glutathione, a biomarker of oxidative stress. In parallel, patients with locally advanced head and neck cancer were enrolled in a phase 1 clinical trial where they consumed KD and received radiation with concurrent platinum-based chemotherapy. Subjects consumed KetoCal KD via percutaneous endoscopic gastrostomy (PEG) tube and were also allowed to orally consume water, sugar-free drinks, and foods approved by a dietitian. Oxidative stress markers including protein carbonyls and total glutathione were assessed in patient blood samples both pre-KD and while consuming the KD. Mice bearing FaDu xenografts that received radiation and KD demonstrated a slight improvement in tumor growth rate and survival compared to mice that received radiation alone; however a variation in responses was seen dependent on the fatty acid composition of the diet. In the phase 1 clinical trial, a total of twelve patients were enrolled in the study. Four patients completed five weeks of the KD as per protocol (with variance in compliance). Eight patients did not tolerate the diet with concurrent radiation and platinum-chemotherapy (5 were patient decision and 3 were removed from study due to toxicity). The median number of days consuming a KD in patients who did not complete the study was 5.5 (range: 2-8 days). Reasons for discontinuation included "stress of diet compliance" (1 patient), grade 2 nausea (3 patients), and grade 3 fatigue (1 patient). Three patients were removed from the trial due to dose-limiting toxicities including: grade 4 hyperuricemia (2 patients) and grade 3 acute pancreatitis (1 patient). Median weight loss was 2.95% for the KD-tolerant group and 7.92% for patients who did not tolerate the diet. In conclusion, the ketogenic diet shows promise as a treatment combined with radiation in preclinical mouse head and neck cancer xenografts. A phase 1 clinical trial evaluating the safety and tolerability of KD demonstrated difficulty with diet compliance when combined with standard-of-care radiation therapy and cisplatin chemotherapy.
- Published
- 2021
- Full Text
- View/download PDF
39. The potential role of MR-guided adaptive radiotherapy in pediatric oncology: Results from a SIOPE-COG survey
- Author
-
Arnold C. Paulino, Henry Mandeville, Cem Onal, Frank Paulsen, Petra S. Kroon, John M. Buatti, Daniel Saunders, Matthew Hall, Enrica Seravalli, Karen J. Marcus, Derek S. Tsang, Enis Ozyar, Geert O. Janssens, Suzanne L. Wolden, and Acibadem University Dspace
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,R895-920 ,Context (language use) ,MR-guided radiotherapy ,Pediatrics ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Medical physics. Medical radiology. Nuclear medicine ,0302 clinical medicine ,Cog ,medicine ,Radiology, Nuclear Medicine and imaging ,Adaptive radiotherapy ,Prospective cohort study ,RC254-282 ,Outcome ,Response rate (survey) ,medicine.diagnostic_test ,Toxicity ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Magnetic resonance imaging ,Radiation therapy ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Radiology ,business - Abstract
Highlights • An international survey assessed the potential role of MRgRT in pediatrics. • The Dutch National cohort has been used to put results into a clinical perspective. • A potential toxicity/outcome benefit is expected for 55%/24% of primary sites. • A potential toxicity/outcome benefit is expected for 62%/38% of metastatic sites. • Consortium-based collaboration is essential to validate expectations., Background and purpose Magnetic resonance guided radiotherapy (MRgRT) has been successfully implemented for several routine clinical applications in adult patients. The purpose of this study is to map the potential benefit of MRgRT on toxicity reduction and outcome in pediatric patients treated with curative intent for primary and metastatic sites. Materials and methods Between May and August 2020, a survey was distributed among SIOPE- and COG-affiliated radiotherapy departments, treating at least 25 pediatrics patients annually and being (candidate) users of a MRgRT system. The survey consisted of a table with 45 rows (clinical scenarios for primary (n = 28) and metastatic (n = 17) tumors) and 7 columns (toxicity reduction, outcome improvement, PTV margin reduction, target volume daily adaptation, online re-planning, intrafraction motion compensation and on-board functional imaging) and the option to answer by ‘yes/no’ . Afterwards, the Dutch national radiotherapy cohort was used to estimate the percentage of pediatric treatments that may benefit from MRgRT. Results The survey was completed by 12/17 (71% response rate) institutions meeting the survey inclusion criteria. Responders indicated an ‘expected benefit’ from MRgRT for toxicity/outcome in 7% (for thoracic lymphomas and abdominal rhabdomyosarcomas)/0% and 18% (for mediastinal lymph nodes, lymph nodes located in the liver/splenic hilum, and liver metastases)/0% of the considered scenarios for the primary and metastatic tumor sites, respectively, and a ‘possible benefit’ was estimated in 64%/46% and 47%/59% of the scenarios. When translating the survey outcome into a clinical perspective a toxicity/outcome benefit, either expected or possible, was anticipated for 55%/24% of primary sites and 62%/38% of the metastatic sites. Conclusion Although the benefit of MRgRT in pediatric radiation oncology is estimated to be modest, the potential role for reducing toxicity and improving clinical outcomes warrants further investigation. This fits best within the context of prospective studies or registration trials.
- Published
- 2021
40. Pediatrics
- Author
-
Lillian Lai, Toshio Moritani, Satsuki Matsumoto, Mariko Sato, Jeremy D. Greenlee, and John M. Buatti
- Published
- 2021
- Full Text
- View/download PDF
41. Abstract 811: Pharmacologic ascorbate opens a therapeutic window for ATM inhibition and radiotherapy in colorectal cancer
- Author
-
Cameron M. Callaghan, Ibrahim M. Abukhiran, Richard V. Van Rheeden, Amanda L. Kalen, Samuel N. Rodman, Michael S. Petronek, Kranti A. Mapuskar, Sarah L. Mott, Mitchell C. Coleman, Prabhat C. Goswami, John M. Buatti, Bryan G. Allen, Douglas R. Spitz, and Joseph M. Caster
- Subjects
Cancer Research ,Oncology - Abstract
Purpose/Objective(s): The ATM protein is key to DNA double strand break (DSB) repair and ATM inhibitors are potent radiosensitizers. Clinical translation of these agents in combination with radiotherapy (RT) has been limited due to concerns for increased normal tissue toxicity. Pharmacologic Ascorbate (P-AscH-) radiosensitizes cancer cells via generation of a H2O2 flux while acting as a radioprotector in normal tissue via free radicle scavenging. We hypothesized that P-AscH- could open a therapeutic window for the combination of RT and ATM inhibition in colorectal cancer (CRC). Materials/Methods: Multiple human and murine CRC cell lines were used in vitro. Clonogenic survival was assessed after combinations of RT +/- P-AscH and DNA Repair Inhibitors (DRIs). Catalase expression was induced using HCT116 cells expressing a doxycycline-inducible catalase transgene. DSBs were quantified using neutral comet assays. Cell cycle distribution were assessed using flow cytometry. ATM localization/activation were assessed using IF. Normal tissue toxicity in vivo was assessed using IHC following whole-abdominal RT. Survival and tumor growth delay was assessed following 5Gyx3 +/- drug treatment to unilateral flank tumors in syngeneic/xenograft models. Results: DRIs were potent radiosensitizers in most CRC cell lines and the addition of P-AscH- further reduced clonogenic survival. In contrast, P-AscH- did not radiosensitize HUVEC or FHs-74int normal cell lines. P-AscH- significantly increased the number of DSBs in tumors after RT in vitro. P-AscH- simultaneously decreased nuclear localization and activation of pATM after RT and perturbed G2+M phase progression. In vivo, the addition of P-AscH- to RT + KU60019 significantly increased survival delayed tumor growth in syngeneic/xenograft models while ameliorating increased normal bowel toxicity as measured by jejunal crypt density, acute weight loss, rectal injury, and markers of oxidative stress following whole-abdominal RT. The effects of P-AscH were reversed by inducing the overexpression of catalase. Conclusion: P-AscH- improves both aspects of the therapeutic window of RT+ATM inhibition in CRC by simultaneously enhancing tumor efficacy while decreasing RT-mediated bowel toxicity. The effects of P-AscH- on clonogenic survival, initial and persistent DSBs, G2+M phase perturbations, ATM activation/localization, and in vivo survival and tumor growth delay were dependent on H202 flux. Normal tissue protection appears to be related to decreased oxidative stress. Citation Format: Cameron M. Callaghan, Ibrahim M. Abukhiran, Richard V. Van Rheeden, Amanda L. Kalen, Samuel N. Rodman, Michael S. Petronek, Kranti A. Mapuskar, Sarah L. Mott, Mitchell C. Coleman, Prabhat C. Goswami, John M. Buatti, Bryan G. Allen, Douglas R. Spitz, Joseph M. Caster. Pharmacologic ascorbate opens a therapeutic window for ATM inhibition and radiotherapy in colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 811.
- Published
- 2022
- Full Text
- View/download PDF
42. The Rapid Evolution of Theranostics in Radiation Oncology
- Author
-
Ana P. Kiess and John M. Buatti
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,MEDLINE ,Oncology ,Neoplasms ,Radiation oncology ,Radiation Oncology ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Precision Medicine ,business - Published
- 2020
43. A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus Document
- Author
-
Daniel A. Pryma, Ronald D. Ennis, Josh Mailman, Yusuf Menda, John M. Buatti, Gerald A. White, Neeta Pandit-Taskar, and Ana P. Kiess
- Subjects
Cancer Research ,medicine.medical_specialty ,Quantitative imaging ,Consensus ,Population ,MEDLINE ,Aftercare ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Multidisciplinary approach ,Neoplasms ,Patient-Centered Care ,Radiation oncology ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,education ,Referral and Consultation ,Patient Care Team ,education.field_of_study ,Radiation ,business.industry ,Patient Selection ,Radiotherapy Planning, Computer-Assisted ,Cornerstone ,Clinical trial ,Oncology ,030220 oncology & carcinogenesis ,Radiopharmaceuticals ,business ,Patient centered - Abstract
Radiopharmaceutical therapy (RPT) is an area of projected growth and importance with several agents in clinical use, new agents in late-phase clinical trials, and many others under testing and development. This article proposes a framework for developing pathways of care that can be broadly applied to all RPTs, representing the current status of RPT. It suggests foundational elements for many pathways of care for patients with cancer and concludes with areas in active development and the future horizon for RPT treatment centers. Developing a framework for patient-centered pathways of care is a critical step in establishing RPT as standard therapy for patients with a diverse spectrum of cancers. This expected increase in RPT treatment options will affect a much larger population of patients with complex cancer. It will also require enhanced coordination and collaboration among appropriately qualified personnel with diverse expertise in image acquisition, image interpretation, quantitative imaging, dosimetry calculation, radiation quality assurance and safety as well as oncology care and RPT-induced sequelae and response assessment. The essential role of this evolving RPT care team within multidisciplinary oncology care is a cornerstone of this framework for a patient-centered pathway of care for RPT. Given the status of current RPT practice and the horizon for future applications, this patient-centered pathway of care guidance is timely and should help inform future clinical RPT practice paradigms. A task force was recruited from the Theranostic Working Group of the American Society for Radiation Oncology (ASTRO) in May 2019 with equal representation from the nuclear medicine community. The task force expanded on a framework that was originally conceived by the Working Group for patient-centered care. This framework was developed to incorporate the strengths of both radiation oncologists and nuclear medicine physicians. The manuscript was then developed by the task force and posted on the ASTRO website for a 6-week public comment period ending in July 2020. Comments were adjudicated, and the draft was sent to external organizations for potential endorsement. This document was sent to the ASTRO Board of Directors in October 2020 for approval.
- Published
- 2020
44. Assessment of Gadobutrol Safety in Combination with Ionizing Radiation Using a Preclinical MRI-Guided Radiotherapy Model
- Author
-
Amanda L. Kalen, Douglas R. Spitz, Joel St-Aubin, Dan E. Hyer, Vincent A. Magnotta, Emily J. Steinbach, C.M. Callaghan, Diana Zepeda-Orozco, John M. Buatti, Zachariah J. Builta, Bryan G. Allen, Ryan T. Flynn, and Michael S. Petronek
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Biophysics ,Renal function ,Contrast Media ,Gadolinium ,Kidney ,Article ,030218 nuclear medicine & medical imaging ,Ionizing radiation ,Gadobutrol ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Radiation, Ionizing ,medicine ,Organometallic Compounds ,Animals ,Humans ,Radiology, Nuclear Medicine and imaging ,Radiation treatment planning ,Blood urea nitrogen ,Radiation ,medicine.diagnostic_test ,business.industry ,Acute kidney injury ,Brain ,Magnetic resonance imaging ,Acute Kidney Injury ,medicine.disease ,Magnetic Resonance Imaging ,Radiation therapy ,Disease Models, Animal ,030220 oncology & carcinogenesis ,Radiology ,business ,medicine.drug ,Radiotherapy, Image-Guided - Abstract
MR-linac technology enhances the precision of therapeutic radiation by clarifying the tumor-normal tissue interface and provides the potential for adaptive treatment planning. Accurate delineation of tumors on diagnostic magnetic resonance imaging (MRI) frequently requires gadolinium-based contrast agents (GBCAs). Despite generally being considered safe, previous literature suggests that GBCAs are capable of contrast-induced acute kidney injury (AKI). It is unclear if the risk for AKI is enhanced when GBCAs are administered concurrently with ionizing radiotherapy. During irradiation, gadolinium may be liberated from its chelator which may induce AKI. The goal of this work was to determine if radiation combined with GBCAs increased the incidence of AKI. Using a preclinical MRI-guided irradiation system, where MRI acquisitions and radiation delivery are performed in rapid succession, tumor-bearing mice with normal kidney function were injected with GBCA and treated with 2, 8 or 18 Gy irradiation. Renal function was assessed on days three and seven postirradiation to assess for AKI. No clinically relevant changes in blood urea nitrogen and creatinine were observed in any combination of GBCA and radiation dose. From these data, we conclude that GBCA in combination with radiation does not increase the risk for AKI in mice. Additional investigation of multiple doses of GBCA administered concurrently with irradiation is warranted to evaluate the risk of chronic kidney injury.
- Published
- 2020
45. Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapy
- Author
-
Daniel J. Berg, Bryan G. Allen, Kellie L. Bodeker, Garry R. Buettner, Emyleigh Opat, Mark C. Smith, Joel St-Aubin, Douglas R. Spitz, Nancy J. Hollenbeck, Cameron Cushing, Ryan T. Flynn, Matthew A. Howard, Jeremy D.W. Greenlee, Heather Brown, Muhammad Furqan, Michael S. Petronek, Vincent A. Magnotta, Kranti A. Mapuskar, John M. Buatti, Sandy Vollstedt, Varun Monga, Brian J. Smith, Joseph J. Cullen, and Thomas Shanks
- Subjects
0301 basic medicine ,inorganic chemicals ,Iron ,Clinical Biochemistry ,T2 ,Phases of clinical research ,Iron redox ,Quantitative imaging ,Biochemistry ,GBM ,03 medical and health sciences ,0302 clinical medicine ,Nuclear magnetic resonance ,medicine ,Progression-free survival ,lcsh:QH301-705.5 ,Radio chemotherapy ,lcsh:R5-920 ,Temozolomide ,medicine.diagnostic_test ,Chemistry ,Organic Chemistry ,QSM ,Brain ,Quantitative susceptibility mapping ,Magnetic resonance imaging ,Magnetic Resonance Imaging ,Pharmacological ascorbate ,030104 developmental biology ,lcsh:Biology (General) ,Biomarker (medicine) ,sense organs ,lcsh:Medicine (General) ,Oxidation-Reduction ,030217 neurology & neurosurgery ,Biomarkers ,medicine.drug ,Research Paper - Abstract
Pharmacological ascorbate (P-AscH-) combined with standard of care (SOC) radiation and temozolomide is being evaluated in a phase 2 clinical trial (NCT02344355) in the treatment of glioblastoma (GBM). Previously published data demonstrated that paramagnetic iron (Fe3+) catalyzes ascorbate's oxidation to form diamagnetic iron (Fe2+). Because paramagnetic Fe3+ may influence relaxation times observed in MR imaging, quantitative MR imaging of P-AscH--induced changes in redox-active Fe was assessed as a biomarker for therapy response. Gel phantoms containing either Fe3+ or Fe2+ were imaged with T2* and quantitative susceptibility mapping (QSM). Fifteen subjects receiving P-AscH- plus SOC underwent T2* and QSM imaging four weeks into treatment. Subjects were scanned: pre-P-AscH- infusion, post-P-AscH- infusion, and post-radiation (3–4 h between scans). Changes in T2* and QSM relaxation times in tumor and normal tissue were calculated and compared to changes in Fe3+ and Fe2+ gel phantoms. A GBM mouse model was used to study the relationship between the imaging findings and the labile iron pool. Phantoms containing Fe3+ demonstrated detectable changes in T2* and QSM relaxation times relative to Fe2+ phantoms. Compared to pre-P-AscH-, GBM T2* and QSM imaging were significantly changed post-P-AscH- infusion consistent with conversion of Fe3+ to Fe2+. No significant changes in T2* or QSM were observed in normal brain tissue. There was moderate concordance between T2* and QSM changes in both progression free survival and overall survival. The GBM mouse model showed similar results with P-AscH- inducing greater changes in tumor labile iron pools compared to the normal tissue. Conclusions T2* and QSM MR-imaging responses are consistent with P-AscH- reducing Fe3+ to Fe2+, selectively in GBM tumor volumes and represent a potential biomarker of response. This study is the first application using MR imaging in humans to measure P-AscH--induced changes in redox-active iron., Highlights • Quantitative imaging can detect tissue differences in Fe3+ and Fe2+ concentrations. • Pharmacological ascorbate treatment increases T2* relaxation times in GBM tumors. • T2* is a potential biomarker of response in GBM subjects to treatment with pharmacological ascorbate.
- Published
- 2020
46. Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network
- Author
-
Hannah M. Linden, Lubomir Hadjiyski, Darrell Tata, Matthias Holdhoff, Ella F. Jones, Hui-Kuo Shu, Richard L. Wahl, Brenda F. Kurland, David A. Mankoff, Daniel L. Rubin, Lawrence H. Schwartz, John M. Buatti, and Robert J. Nordstrom
- Subjects
Diagnostic Imaging ,medicine.medical_specialty ,Quantitative imaging ,Computer science ,Harmonization ,Review Article ,Quantitative Imaging Network (QIN) ,Neoplasms ,Radiation oncology ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,Clinical Trial Design and Development (CTDD) ,Randomized Controlled Trials as Topic ,Clinical Trials as Topic ,Clinical study design ,Test (assessment) ,Clinical trial ,Outreach ,Work (electrical) ,Clinical Trials, Phase III as Topic ,Positron-Emission Tomography ,Radiation Oncology ,Tomography, X-Ray Computed - Abstract
The Clinical Trial Design and Development Working Group within the Quantitative Imaging Network focuses on providing support for the development, validation, and harmonization of quantitative imaging (QI) methods and tools for use in cancer clinical trials. In the past 10 years, the Group has been working in several areas to identify challenges and opportunities in clinical trials involving QI and radiation oncology. The Group has been working with Quantitative Imaging Network members and the Quantitative Imaging Biomarkers Alliance leadership to develop guidelines for standardizing the reporting of quantitative imaging. As a validation platform, the Group led a multireader study to test a semi-automated positron emission tomography quantification software. Clinical translation of QI tools cannot be possible without a continuing dialogue with clinical users. This article also highlights the outreach activities extended to cooperative groups and other organizations that promote the use of QI tools to support clinical decisions.
- Published
- 2020
- Full Text
- View/download PDF
47. Stereotactic radiotherapy of appropriately selected meningiomas and metastatic brain tumor beds with gamma knife icon versus volumetric modulated arc therapy
- Author
-
B. Gross, Jacob S. Buatti, Mark C. Smith, Edward C. Pennington, Joel St-Aubin, Ryan T. Flynn, Dongxu Wang, Daniel E. Hyer, Sridhar Yaddanapudi, and John M. Buatti
- Subjects
Organs at Risk ,tumor bed ,gamma knife ,Brain tumor ,Gamma knife ,meningioma ,030218 nuclear medicine & medical imaging ,Meningioma ,Stereotactic radiotherapy ,volumetric modulated arc therapy ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Meningeal Neoplasms ,Humans ,Radiology, Nuclear Medicine and imaging ,Tumor bed ,Radiation treatment planning ,Instrumentation ,Radiation ,Original Communication ,business.industry ,Brain Neoplasms ,Radiotherapy Planning, Computer-Assisted ,Radiotherapy Dosage ,medicine.disease ,Volumetric modulated arc therapy ,Great vessels ,030220 oncology & carcinogenesis ,stereotactic radiotherapy ,Radiotherapy, Intensity-Modulated ,business ,Nuclear medicine - Abstract
Purpose To determine if the gamma knife icon (GKI) can provide superior stereotactic radiotherapy (SRT) dose distributions for appropriately selected meningioma and post‐resection brain tumor bed treatments to volumetric modulated arc therapy (VMAT). Materials and Methods Appropriately selected targets were not proximal to great vessels, did not have sensitive soft tissue including organs‐at‐risk (OARs) within the planning target volume (PTV), and did not have concave tumors containing excessive normal brain tissue. Four of fourteen candidate meningioma patients and six of six candidate patients with brain tumor cavities were considered for this treatment planning comparison study. PTVs were generated for GKI and VMAT by adding 1 mm and 3 mm margins, respectively, to the GTVs. Identical PTV V100%‐values were obtained for the GKI and VMAT plans for each patient. Meningioma and tumor bed prescription doses were 52.7–54.0 in 1.7–1.8 Gy fractions and 25 Gy in 5 Gy fractions, respectively. GKI dose rate was 3.735 Gy/min for 16 mm collimators. Results PTV radical dose homogeneity index was 3.03 ± 0.35 for GKI and 1.27 ± 0.19 for VMAT. Normal brain D 1%, D 5%, and D 10% were lower for GKI than VMAT by 45.8 ± 10.9%, 38.9 ± 11.5%, and 35.4 ± 16.5% respectively. All OARs considered received lower maximum doses for GKI than VMAT. GKI and VMAT treatment times for meningioma plans were 12.1 ± 4.13 min and 6.2 ± 0.32 min, respectively, and, for tumor cavities, were 18.1 ± 5.1 min and 11.0 ± 0.56 min, respectively. Conclusions Appropriately selected meningioma and brain tumor bed patients may benefit from GKI‐based SRT due to the decreased normal brain and OAR doses relative to VMAT enabled by smaller margins. Care must be taken in meningioma patient selection for SRT with the GKI, even if they are clinically appropriate for VMAT.
- Published
- 2020
48. The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma
- Author
-
Michael S. Petronek, Carryn M. Anderson, Bryan G. Allen, Steven N. Seyedin, I. Mohiuddin, Kelli L. Hawkes, Varun Monga, John M. Buatti, C.M. Callaghan, and Mohammed M. Milhem
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Programmed Cell Death 1 Receptor ,Biophysics ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,Radiosurgery ,Undifferentiated Pleomorphic Sarcoma ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Chondroblastic Osteosarcoma ,Internal medicine ,medicine ,Combined Modality Therapy ,Humans ,Radiology, Nuclear Medicine and imaging ,Neoplasm Metastasis ,Aged ,Radiation ,business.industry ,Abscopal effect ,Common Terminology Criteria for Adverse Events ,Sarcoma ,Middle Aged ,Treatment Outcome ,Response Evaluation Criteria in Solid Tumors ,030220 oncology & carcinogenesis ,business - Abstract
Patients diagnosed with metastatic sarcoma have limited options for achieving both local and distant tumor control. While SBRT can achieve local control, distant response rates remain low. There is limited evidence demonstrating the safety and efficacy for combining SBRT with concurrent PD-1 checkpoint blockade in metastatic sarcoma. In this prospective case-series, we examined five patients with metastatic sarcoma on pembrolizumab treated concurrently with SBRT from July 1, 2016-October 30, 2018. Acute and chronic toxicity were recorded using Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). SBRT-treated tumor control was assessed using Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). With median follow-up of 14.9 months, three patients with undifferentiated pleomorphic sarcoma, one with intimal, and one with chondroblastic osteosarcoma received SBRT with concurrent pembrolizumab to 10 sites of metastatic disease. No grade 5 toxicities were observed. There was a single incidence of transient grade 4 lymphopenia which resolved without intervention. Grade 3 toxicities included anemia, thrombocytopenia, lymphopenia and colitis. One tumor demonstrated local progression after SBRT, and all others remained stable or with response. In conclusion, combining SBRT with PD-1 inhibition appeared to be safe in this patient population. Expected high rates of treated-tumor local control after SBRT were observed. Two of five patients demonstrated either enhanced local tumor regression, or possible abscopal effect.
- Published
- 2020
49. Differentiated Thyroid Cancer: Management and Treatment in a Community Hospital and Guidelines to Lower Morbidity
- Author
-
Dwayne Capper, Hamed H. Tewfik, Thomas Viner, Ferial A. Tewfik, and John M. Buatti
- Subjects
Total thyroidectomy ,Pediatrics ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,General Engineering ,Levothyroxine ,Ocean Engineering ,medicine.disease ,Community hospital ,Quality of life ,medicine ,Cost of treatment ,Very low risk ,business ,Adjuvant ,Thyroid cancer ,medicine.drug - Abstract
Total thyroidectomy and adjuvant RIT followed by a suppressive dose of levothyroxine are the established therapeutic procedures of choice for DTC. The treatment of DTC has changed from a one size fits all standard to a more individualized approach. The use of less complete surgery as well as decision to use RIT and the dose administered are to be considered carefully in the treatment of DTC. Surveillance for very low risk DTC is an acceptable option. The aim to lower morbidity, lower the cost of treatment and improve patient quality of life is attainable using these principles.
- Published
- 2020
- Full Text
- View/download PDF
50. Long-term outcome comparison for standard fractionation (>59 Gy) versus hyperfractionated (>45 Gy) radiotherapy plus concurrent chemotherapy for limited-stage small-cell lung cancer
- Author
-
Amir Zahra, Daniel J. Herr, Bryan G. Allen, Anand K. Sharma, Sarah L. Mott, Nicholas S. Andresen, Coyt R. Rountree, John M. Buatti, Jacy O’Keefe, John M. Watkins, and J. Kyle Russo
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,medicine.disease ,Small-cell carcinoma ,030218 nuclear medicine & medical imaging ,Radiation therapy ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Biopsy ,medicine ,Combined Modality Therapy ,Radiology, Nuclear Medicine and imaging ,Radiology ,Original Research Article ,Prophylactic cranial irradiation ,Lung cancer ,business ,Hyperfractionation - Abstract
Background Concurrent chemoradiotherapy (CCRT) is commonly employed in limited-stage small-cell lung cancer (LS-SCLC); however, the optimal radiotherapy regimen is still unknown. This 3-institution analysis compares long-term disease control and survival outcomes for once- (QD) versus twice-daily (BID) radiotherapy at contemporary doses. Methods and Materials Data were collected for LS-SCLC patients treated with platinum-based CCRT and planned RT doses of > 5940 cGy at > 180 cGy QD or > 4500 cGy at 150 cGy BID. Comparative outcome analyses were performed for treatment groups. Results From 2005 through 2014, 132 patients met inclusion criteria for analysis (80 QD, 52 BID). Treatment groups were well-balanced, excepting higher rate of advanced mediastinal staging, longer interval from biopsy to treatment initiation, and lower rate of prophylactic cranial irradiation for the QD group, as well as institutional practice variation. At median survivor follow-up of 33.5 months (range, 4.6–105.8), 80 patients experienced disease failure (44 QD, 36 BID), and 106 died (62 QD, 44 BID). No differences in disease control or survival were demonstrated between treatment groups. Conclusion The present analysis did not detect a difference in disease control or survival outcomes for contemporary dose QD versus BID CCRT in LS-SCLC.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.